1. Home
  2. SNGX vs VVOS Comparison

SNGX vs VVOS Comparison

Compare SNGX & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.38

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Logo Vivos Therapeutics Inc.

VVOS

Vivos Therapeutics Inc.

HOLD

Current Price

$0.41

Market Cap

5.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNGX
VVOS
Founded
1987
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6M
5.5M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
SNGX
VVOS
Price
$0.38
$0.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$2.75
AVG Volume (30 Days)
334.0K
151.7K
Earning Date
05-08-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
57.03
6.76
EPS
N/A
N/A
Revenue
$119,371.00
$17,443,000.00
Revenue This Year
N/A
$69.66
Revenue Next Year
N/A
$48.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.05
52 Week Low
$0.28
$0.36
52 Week High
$6.23
$5.21

Technical Indicators

Market Signals
Indicator
SNGX
VVOS
Relative Strength Index (RSI) 44.32 38.04
Support Level $0.37 $0.37
Resistance Level $0.38 $0.55
Average True Range (ATR) 0.02 0.03
MACD 0.01 0.01
Stochastic Oscillator 71.54 48.17

Price Performance

Historical Comparison
SNGX
VVOS

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Share on Social Networks: